DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Treatment timelines for each major GLP‑1: when appetite changes, when side effects peak, when weight loss accelerates, and when you reach maintenance.
Enter your weight and drug to see a projected weight-loss curve from first dose to maintenance — as an honest range from published trial data, with a lean-mass overlay. Then read the week-by-week timeline below.
A trial-grounded forecast of where the scale could land — shown as a range, not one rosy line, with a lean-mass overlay so you see what kind of weight you’re losing. Inputs stay on your device.
| Milestone | Lost (range) | Weight (mean) |
|---|---|---|
| Week 4 | 4–7 lb | 215 lb |
| Week 24 | 19–32 lb | 195 lb |
| Week 48 | 29–49 lb | 181 lb |
| Week 72maintenance | 34–57 lb | 174 lb |
Of the ~46 lb at the trial mean, about 11.5 lb may be lean mass. Adding resistance training + protein could cut that to 3.7 lb — the muscle you keep.
Where these numbers come from. Terminal mean is 20.9% body-weight loss from SURMOUNT-1 (Jastreboff AM et al, NEJM 2022;387:205-216; n=2,539, 72 wk).
Estimand: on-treatment / trial-completer means — i.e. if you tolerate the drug, reach the studied dose, and stay on it. Intent-to-treat figures (counting people who stop early) are lower. The band is the mean ± ~1 SD of individual response; a meaningful minority lose noticeably less. Individual results vary — this is not a guarantee or medical advice.
Telehealth matcher — filtered by your drug, budget, and state. No account needed.
semaglutide · first dose to maintenance
tirzepatide · first dose to maintenance
semaglutide · first dose to maintenance
tirzepatide · first dose to maintenance
liraglutide · first dose to maintenance
orforglipron · first dose to maintenance